PMGC Holdings Signs Exclusive License Agreement With Modulant for Animal Health Probiotics

Reuters
Feb 12
<a href="https://laohu8.com/S/ELAB">PMGC Holdings</a> Signs Exclusive License Agreement With Modulant for Animal Health Probiotics

PMGC Holdings Inc. announced that its wholly owned subsidiary, NorthStrive Biosciences Inc., has executed a definitive, exclusive license agreement with Modulant Biosciences LLC. The agreement grants Modulant an exclusive, royalty-bearing, sublicensable license to develop, manufacture, and commercialize NorthStrive's EL-22 and EL-32 assets for animal health applications worldwide, excluding the Republic of Korea. Modulant will be responsible for all development, manufacturing, regulatory, and commercialization activities related to the licensed products. The agreement covers issued patents, pending patent applications, and associated proprietary know-how for EL-22 and EL-32.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PMGC Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-015003), on February 11, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10